The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dyslipidemias


Psychiatry related information on Dyslipidemias


High impact information on Dyslipidemias


Chemical compound and disease context of Dyslipidemias


Biological context of Dyslipidemias


Anatomical context of Dyslipidemias


Gene context of Dyslipidemias


Analytical, diagnostic and therapeutic context of Dyslipidemias


  1. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. Garg, A., Grundy, S.M. JAMA (1990) [Pubmed]
  2. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. Vega, G.L., Grundy, S.M. JAMA (1990) [Pubmed]
  3. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. Masuzaki, H., Yamamoto, H., Kenyon, C.J., Elmquist, J.K., Morton, N.M., Paterson, J.M., Shinyama, H., Sharp, M.G., Fleming, S., Mullins, J.J., Seckl, J.R., Flier, J.S. J. Clin. Invest. (2003) [Pubmed]
  4. Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. Miyake, K., Ogawa, W., Matsumoto, M., Nakamura, T., Sakaue, H., Kasuga, M. J. Clin. Invest. (2002) [Pubmed]
  5. Liver-specific reactivation of the inactivated Hnf-1alpha gene: elimination of liver dysfunction to establish a mouse MODY3 model. Lee, Y.H., Magnuson, M.A., Muppala, V., Chen, S.S. Mol. Cell. Biol. (2003) [Pubmed]
  6. Carnitine system in uremic patients: molecular and clinical aspects. Savica, V., Calvani, M., Benatti, P., Santoro, D., Monardo, P., Peluso, G., Bellinghieri, G. Semin. Nephrol. (2004) [Pubmed]
  7. Dietary patterns and the odds of carotid atherosclerosis in women: the Framingham Nutrition Studies. Millen, B.E., Quatromoni, P.A., Nam, B.H., O'Horo, C.E., Polak, J.F., D'Agostino, R.B. Preventive medicine. (2002) [Pubmed]
  8. Dyslipidemia treatment: current considerations and unmet needs. Malik, S., Kashyap, M.L. Expert review of cardiovascular therapy. (2003) [Pubmed]
  9. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. Moghadasian, M.H., McManus, B.M., Nguyen, L.B., Shefer, S., Nadji, M., Godin, D.V., Green, T.J., Hill, J., Yang, Y., Scudamore, C.H., Frohlich, J.J. FASEB J. (2001) [Pubmed]
  10. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., Offermanns, S. Nat. Med. (2003) [Pubmed]
  11. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. Wilson, P.W., Myers, R.H., Larson, M.G., Ordovas, J.M., Wolf, P.A., Schaefer, E.J. JAMA (1994) [Pubmed]
  12. Managing the high-risk patient: therapeutic approaches in 2002. Schuster, H. Atherosclerosis. Supplements. (2003) [Pubmed]
  13. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. Clausen, J.O., Borch-Johnsen, K., Ibsen, H., Bergman, R.N., Hougaard, P., Winther, K., Pedersen, O. J. Clin. Invest. (1996) [Pubmed]
  14. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Barrett-Connor, E. Ann. Intern. Med. (1992) [Pubmed]
  15. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Kopprasch, S., Pietzsch, J., Kuhlisch, E., Fuecker, K., Temelkova-Kurktschiev, T., Hanefeld, M., Kühne, H., Julius, U., Graessler, J. Diabetes (2002) [Pubmed]
  16. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. Haidari, M., Leung, N., Mahbub, F., Uffelman, K.D., Kohen-Avramoglu, R., Lewis, G.F., Adeli, K. J. Biol. Chem. (2002) [Pubmed]
  17. Recognition and management of dyslipidemia in children and adolescents. Kwiterovich, P.O. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  18. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Sam, S., Legro, R.S., Essah, P.A., Apridonidze, T., Dunaif, A. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  19. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Chan, D.C., Watts, G.F., Barrett, P.H., Beilin, L.J., Redgrave, T.G., Mori, T.A. Diabetes (2002) [Pubmed]
  20. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Eberlé, D., Clément, K., Meyre, D., Sahbatou, M., Vaxillaire, M., Le Gall, A., Ferré, P., Basdevant, A., Froguel, P., Foufelle, F. Diabetes (2004) [Pubmed]
  21. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Lee, Y.J., Tsai, J.C. Diabetes Care (2002) [Pubmed]
  22. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. Hansel, B., Giral, P., Nobecourt, E., Chantepie, S., Bruckert, E., Chapman, M.J., Kontush, A. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  23. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Camejo, G., Olsson, U., Hurt-Camejo, E., Baharamian, N., Bondjers, G. Atherosclerosis. Supplements. (2002) [Pubmed]
  24. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Zhao, H., Yakar, S., Gavrilova, O., Sun, H., Zhang, Y., Kim, H., Setser, J., Jou, W., LeRoith, D. Diabetes (2004) [Pubmed]
  25. The translational regulation of lipoprotein lipase in diabetic rats involves the 3'-untranslated region of the lipoprotein lipase mRNA. Ranganathan, G., Li, C., Kern, P.A. J. Biol. Chem. (2000) [Pubmed]
  26. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Reifel-Miller, A., Otto, K., Hawkins, E., Barr, R., Bensch, W.R., Bull, C., Dana, S., Klausing, K., Martin, J.A., Rafaeloff-Phail, R., Rafizadeh-Montrose, C., Rhodes, G., Robey, R., Rojo, I., Rungta, D., Snyder, D., Wilbur, K., Zhang, T., Zink, R., Warshawsky, A., Brozinick, J.T. Mol. Endocrinol. (2005) [Pubmed]
  27. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Le Goff, W., Guerin, M., Chapman, M.J. Pharmacol. Ther. (2004) [Pubmed]
  28. USF1 and dyslipidemias: converging evidence for a functional intronic variant. Naukkarinen, J., Gentile, M., Soro-Paavonen, A., Saarela, J., Koistinen, H.A., Pajukanta, P., Taskinen, M.R., Peltonen, L. Hum. Mol. Genet. (2005) [Pubmed]
  29. The mechanisms of action of PPARs. Berger, J., Moller, D.E. Annu. Rev. Med. (2002) [Pubmed]
  30. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Reichlin, M., Fesmire, J., Quintero-Del-Rio, A.I., Wolfson-Reichlin, M. Arthritis Rheum. (2002) [Pubmed]
  31. A broad role for the zinc finger protein ZNF202 in human lipid metabolism. Wagner, S., Hess, M.A., Ormonde-Hanson, P., Malandro, J., Hu, H., Chen, M., Kehrer, R., Frodsham, M., Schumacher, C., Beluch, M., Honer, C., Skolnick, M., Ballinger, D., Bowen, B.R. J. Biol. Chem. (2000) [Pubmed]
  32. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. Guettier, J.M., Georgopoulos, A., Tsai, M.Y., Radha, V., Shanthirani, S., Deepa, R., Gross, M., Rao, G., Mohan, V. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  33. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Avram, M.M., Fein, P.A., Antignani, A., Mittman, N., Mushnick, R.A., Lustig, A.R., Lapuz, M.H., Goldwasser, P. Am. J. Med. (1989) [Pubmed]
  34. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. Schwartz, R.G., Pearson, T.A., Kalaria, V.G., Mackin, M.L., Williford, D.J., Awasthi, A., Shah, A., Rains, A., Guido, J.J. J. Am. Coll. Cardiol. (2003) [Pubmed]
  35. Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Dixon, J.L., Stoops, J.D., Parker, J.L., Laughlin, M.H., Weisman, G.A., Sturek, M. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  36. Lower-body adiposity and metabolic protection in postmenopausal women. Van Pelt, R.E., Jankowski, C.M., Gozansky, W.S., Schwartz, R.S., Kohrt, W.M. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  37. Liver pathology and the metabolic syndrome X in severe obesity. Marceau, P., Biron, S., Hould, F.S., Marceau, S., Simard, S., Thung, S.N., Kral, J.G. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
WikiGenes - Universities